Menu

Clinical research

181209-EUPHRATES-653x337px

EUPHRATES Trial Publication

A new article concerning EUPHRATES trial results has been published in Intensive Care Medicine. This Post Hoc analysis follows the results concerning the Overall Population, published previously in JAMA.
This marks another step forward in septic shock research and in the accumulation of evidence for Polymyxin B hemoperfusion as precision therapy in selected patients.

clinical-research-653x337

EUPHRATES RESULTS PRESENTATION – VICENZA COURSE 2017

At the 35th VICENZA COURSE on AKI and CRRT organized by Professor Claudio Ronco, held in Vicenza 13th–16th June, Professor Massimo Antonelli, President of the European Society of Intensive Care Medicine (ESICM) and member of the EUPHRATES trial steering committee, will present results from the EUPHRATES trial on Polymyxin B hemoperfusion in septic shock patients on 14th June at 17.30.

clinical-research-653x337

EUPHRATES trial – UPDATE

The fourth and final module of PMA application for FDA approval of Toraymyxin® has been submitted. A further data analysis of the EUPHRATES database identifies a population with significant mortality benefit when treated with Polymyxin B hemoperfusion therapy.

clinical-research-653x337

EUPHRATES RCT

EUPHRATES, an RCT performed in the USA and Canada on Polymyxin B hemoperfusion therapy (Toraymyxin®) has finished enrolment and the first results on the primary endpoints have recently been announced in a press release.

euphas2-web-registry-653x337

EUPHAS 2 WEB REGISTRY

EUPHAS 2 is a web-based registry for the collection of clinical data from patients undergoing Polymyxin B hemoperfusion therapy (Toraymyxin®). Data from 357 patients recorded during the first phase have been published recently in Annals of Intensive Care Medicine.